Toll-free road from sepsis
Main Category: Infectious Diseases / Bacteria / VirusesArticle Date: 18 May 2004 - 0:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes.
Immune system failure to limit the spread of a bacterial infection results in sepsis: a loss of control on the normal inflammatory response, leading to tissue damage, increased vascular permeability, and finally multi-organ failure and shock.
The death rate for sepsis patients is in the range of 70%, and the health-care sticker price for such runaway infections is around $15 billion annually in the US alone. Strategies for treating septic shock are aimed at limiting the inflammatory response, as treatments to directly reduce the bacterial infection, such as the use of antibiotics, can result in furthering the already out-of-control inflammatory response.
Now, Cartson Kirschning and colleagues, from the Technical University of Munich, have tested a new therapeutic possibility by creating antibodies directed against the receptor to which bacteria bind in order to infect the cell. The strategy here, therefore, is to interrupt the initial step of septic inflammation.
They showed that use of antibodies against the toll-like receptor 2 (TLR2) in lipopeptide-challenged mice blocked the release of markers of the inflammatory response, such as TNFalpha, and protected the mice from a lethal shock-like syndrome. The results here indicate the potential suitability for antibody-directed therapy in treating septic shock.
An accompanying commentary by Thomas Decker, of the University of Vienna, provides an overview of Toll-like receptors, their role in bacterial infection, and a discussion of the potential strengths and weaknesses of targeting these receptors for combating sepsis.
TITLE: Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes
AUTHOR CONTACT:
Carsten J. Kirschning
Technical University of Munich, Munich, Germany.
Phone: +49-89-4140-4132; Fax: +49-89-4140-4139; E-mail: carsten.kirschning@lrz.tum.de
View the PDF of this article at: https://www.the-jci.org/press/20762.pdf
ACCOMPANYING COMMENTARY: Sepsis: avoiding its deadly toll
AUTHOR CONTACT:
Thomas Decker
University of Vienna, Vienna, Austria.
Phone: +43-1-4277-54605; Fax: +43-1-4277-9546; E-mail: thomas.decker@univie.ac.at
View the PDF of this commentary at: https://www.the-jci.org/press/21819.pdf
Contact: Laurie Goodman
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/8407.php>
APA
http://www.medicalnewstoday.com/releases/8407.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



